1. Scrip
  2. >>Conferences
  3. >>BIO

AI Is Inevitable, But Useful Only If Solves The Right Problems

Artificial Intelligence A Big Topic At BIO

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

Merck & Co.'s TEDDY AI models aim to unlock insights into gene regulatory networks (Shutterstock)

Artificial intelligence-enabled drug discovery and development is one of the hottest topics in the biopharmaceutical industry, capturing the imaginations of investors, entrepreneurs and veterans alike. While it is too early to say that the AI field has matured, it has grown enough for innovators in the space and ongoing adopters of the technology to better understand which pain points in the drug development process it may help alleviate.

Key Takeaways
  • Scrip spoke with executives from Merck & Co., Valo Health and Generate:Biomedicines about their artificial intelligence strategies at the BIO International Convention, where AI was a hot topic.

With AI as a prominent topic during the recent BIO International Convention, Scrip spoke with companies at the conference that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from BIO

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

 
• By Mandy Jackson

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.